ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

The global sleep apnea devices market is set to expand at a steady CAGR of 9.5%, growing from USD 8.2 billion in 2023 to USD ...

My wife, who bore the brunt of my transformation into a grumpy badger, was the first to suggest I get a sleep study. She’d ...

According to statistics by the American Association of Medicine, the disorder sleep apnea affects approximately 30 million US ...

For patients with obstructive sleep apnea (OSA), sleep surgery is associated with a significantly reduced risk for mo ...

Compromised sleep continuity and initiation may underlie the link between depression and difficulty sleeping among older adults.

Taking too long to enter the phase of sleep in which we dream may be an early sign of Alzheimer's disease. This is the ...

The thought of dying in your sleep has probably crossed your mind more than once. It’s a terrifying idea — one you’d rather ...

Key Takeaways Untreated sleep apnea contributes to car crashesPatients who got no treatment were 21% more likely to be in a ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.